| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38bbf98d4506cc0b660f2d08349466c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86c227a1644c83553c5f9b1fba0fa63d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6e39fb647151c551654257ee972cf09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a77b8cc427db284b23b54636b37e89a0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate |
2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a6518424f316de1ca2318369d0f3b35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_412cd913b9aa1dedf4851e3aa9097495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90aa5429cb2b39d02e6057fcbc59dd71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2333579b560feba611b407d1edb0de7 |
| publicationDate |
2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012067913-A1 |
| titleOfInvention |
Local vascular delivery of an adenosine a2a receptor agonist / phosphodiesterase inhibitor combination to reduce myocardial injury |
| abstract |
A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized in combination with other therapeutic agents to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position, the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist alone or in combination with other therapeutic agents elute from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury. |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |